Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model

Journal of the Peripheral Nervous System

Volumn 16, Issue 3, 2011, Pages 199-212

  Bruna, Jordi ^a,b,c   Alé, Albert ^a,b   Velasco, Roser ^a,b,c   Jaramillo, Jessica ^a,b   Navarro, Xavier ^a,b   Udina, Esther ^a,b  

^a INSTITUT DE NEUROCIÈNCIES   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

bortezomib; mice; pre existing neuropathy; vincristine

Indexed keywords

BORTEZOMIB; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EVALUATION; DISEASE SEVERITY; FEMALE; MOUSE; MYELINATED NERVE; NERVE FUNCTION; NONHUMAN; NONMYELINATED NERVE; PAIN ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SENSORIMOTOR NEUROPATHY; SKIN NERVE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; NEUROTOXICITY SYNDROMES; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RISK FACTORS;

EID: 80055022994     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2011.00346.x     Document Type: Article

References (58)

1. Argyriou AA, Iconomou G, Kalofonos HP, (2008). Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112: 1593-1599.
2. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F, (2003). A new animal model of vincristine-induced nociceptive peripheral neuropathy. Neurotoxicology 24: 797-805. (Pubitemid 37486255)
3. Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, Coudore F, Bourinet E, Eschalier A, (2009). Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 6: 620-629.
4. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG, (2007). Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110: 1042-1049. (Pubitemid 47312870)
5. Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K, (2005). Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 104: 2141-2148. (Pubitemid 41579960)
6. Bruna J, Udina E, Alé A, Vilches JJ, Vynckier A, Monbaliu J, Silverman L, Navarro X, (2010). Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 223: 599-608.
7. Callizot N, Andriambeloson E, Glass J, Revel M, Ferro P, Cirillo R, Vitte PA, Dreano M, (2008). Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity. Cancer Chemother Pharmacol 62: 995-1007.
8. Carde P, MacKintosh FR, Rosenberg SA, (1983). A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1: 146-153. (Pubitemid 14176804)
9. Casafont I, Berciano MT, Lafarga M, (2009). Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res 17: 167-178.
10. Casey EB, Jellife AM, Le Quesene PM, Millet YL, (1973). Vincristine neuropathy. Clinical and electrophysiological observations. Brain 96: 69-86.
11. Carozzi VA, Canta A, Oggioni N, Sala B, Chiorazzi A, Meregalli C, Bossi M, Marmiroli P, Cavaletti G, (2010). Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Exp Neurol 226: 301-309.
12. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D'Incalci M, De Coster R, (2007). Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in rat. Exp Neurol 204: 317-325. (Pubitemid 46330280)
13. Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P, (2010). Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46: 479-494.
14. Chaudhry V, Chaudhry M, Crawford TO, Simmons-O'Brien E, Griffin JW, (2003). Toxic neuropathy in patients with pre-existing neuropathy. Neurology 60: 337-340. (Pubitemid 36152036)
15. Contreras PC, Vaught JL, Gruner JA, Brosnan C, Steffler C, Arezzo JC, Lewis ME, Kessler JA, Apfel SC, (1997). Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice. Brain Res 774: 20-26. (Pubitemid 28007878)
16. Corso A, Mangiacavalli S, Varettoni M, Pascutto C, Zappasodi P, Lazzarino M, (2010). Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res 34: 471-474.
17. Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF, (2011). Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 86: 23-31.
18. Djaldetti R, Hart J, Alexandrova S, Cohen S, Beilin BZ, Djaldetti M, Bessler H, (1996). Vincristine-induced alterations in Schwann cells of mouse peripheral nerve. Am J Hematol 52: 254-257. (Pubitemid 26288736)
19. El-Cheikh J, Stoppa AM, Bouabdallah R, de Lavallade H, Coso D, de Collela JM, Auran-Schleinitz T, Gastaut JA, Blaise D, Mohty M, (2008). Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced myeloma. Clin Lymphoma Myeloma 8: 146-152.
20. Flatters SJ, Bennett GJ, (2006). Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 122: 245-257. (Pubitemid 43729476)
21. Fukuizumi T, Ohkubo T, Kitamura K, (2003). Spinal sensitization mechanism in vincristine-induced hyperalgesia in mice. Neurosci Lett 343: 89-92. (Pubitemid 36577523)
22. Gauchan P, Andoh T, Ikeda K, Fujita M, Sasaki A, Kato A, Kuraishi Y, (2009). Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha (2) delta-1 subunit. Biol Pharm Bull 32: 732-734.
23. Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM, (2003). Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol 21: 3761-3769. (Pubitemid 46606230)
24. Gómez N, Cuadras J, Butí M, Navarro X, (1996). Histologic assessment of sciatic nerve regeneration following resection and graft or tube repair in the mouse. Restor Neurol Neurosci 10: 187-196. (Pubitemid 27060471)
25. Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD, (1996). Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 77: 1356-1362. (Pubitemid 26102336)
26. Hargreaves K, Dubner R, Brown F, Flores C, Joris J, (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.
27. Ja'afer FM, Hamdan FB, Mohammed FH, (2006). Vincristine-induced neuropathy in rat: electrophysiological and histological study. Exp Brain Res 173: 334-345. (Pubitemid 44264898)
28. Johnson IS, Armstrong JG, Gorman M, Burnett JP, (1963). The vinca alkaloids: a new class of oncolytic agents. Cancer Res 23: 1390-1427.
29. Kalfakis N, Panas M, Karadima G, Floroskufi P, Kokolakis N, Vassilopoulos D, (2002). Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment. Neurology 59: 1470-1471. (Pubitemid 35286016)
30. Kamei J, Nozaki C, Saitoh A, (2006). Effect of mexiletine on vincristine-induced painful neuropathy in mice. Eur J Pharmacol 536: 123-127.
31. Kiguchi N, Maeda T, Kobayashi Y, Kondo T, Ozaki M, Kishioka S, (2008). The critical role of invading peripheral macrophage-derived interleukin-6 in vincristine-induced mechanical allodynia in mice. Eur J Pharmacol 592: 87-92.
32. Lanzani F, Mattavelli L, Frigeni B, Rossini F, Cammarota S, Petrò D, Jann S, Cavaletti G, (2008). Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst 13: 267-274.
33. Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A, Ceresa C, Avezza F, Crippa L, Marmiroli P, Cavaletti G, (2010). Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 14: 343-350.
34. Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M, (2010). Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 95: 311-9.
35. Mollman JE, Glover DJ, Hogan WM, Furman RE, (1988). Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61: 2192-2195.
36. Navarro X, Verdú E, Butí M, (1994). Comparison of regenerating and reinnervating capabilities of different functional types of nerve fibers. Exp Neurol 129: 217-224.
37. Navarro X, Verdú E, Wendelschafer-Crabb G, Kennedy WR, (1995). Innervation of cutaneous structures in the mouse hind paw: a confocal microscopy immunohistochemical study. J Neurosci Res 41: 111-120.
38. Ogawa T, Mimura Y, Isowa K, Kato H, Mitsuishi M, Toyoshi T, Kuwayama N, Morimoto H, Murakoshi M, Nakayama T, (2001). An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models. Toxicol Lett 121: 97-106. (Pubitemid 32452193)
39. Panwalkar A, Verstovsek S, Giles F, (2004). Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer 100: 1578-1589. (Pubitemid 38456332)
40. Plasmati R, Pastorelli F, CAvo M, Petracci E, Zamagnani E, Tosi P, Cangini D, TAcchetti P, Salvi F, Bartolomei I, Michelucci R, Tassinari CA, (2007). Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 69: 573-581. (Pubitemid 47357264)
41. Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T, (2008). Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 7: 940-949. (Pubitemid 351573790)
42. Ramanathan RK, Rothenberg ML, Gramont A, Tournigand C, Goldberg RM, Gupta S, Andre T, (2010). Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol 21: 754-758.
43. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC, (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617. (Pubitemid 36741588)
44. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA, (2006). Frequency, characteristics, and reversibility of peripherals neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24: 3113-3120. (Pubitemid 46638949)
45. Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA, (2009). Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27: 3518-3525.
46. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG, (2008). Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359: 906-917.
47. Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M, Walters IB, Noga SJ, (2009). Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol 84: 657-660.
48. Stubblefield MD, Slovin S, MacGregor-Cortelli B, Muzzy J, Scher H, Wright J, Esseltine D, Schenkein D, O'Connor OA, (2006). An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clin Oncol (R Coll Radiol) 18: 410-418.
49. Thant M, Hawley RJ, Smith M, Cohen MH, Minna JD, Bunn PA, Ihde DC, West W, Matthews MJ, (1982). Possible enhancement of vincristine neuropathy by VP-16. Cancer 49: 859-864. (Pubitemid 12184083)
50. Trobaugh-Lotrario AD, Smith AA, Odom LF, (2003). Vincristine neurotoxicity in the presence of hereditary neuropathy. Med Pediatr Oncol 40: 39-43. (Pubitemid 35340566)
51. Van den Bent MJ, van Putten WLJ, Hilkens PHE, de Wit R, van der Burg MEL, (2002). Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. Eur J Cancer 38: 387-391. (Pubitemid 34121966)
52. Van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, van Houwelingen C, Neijt JP, (1990). Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 66: 1697-1702. (Pubitemid 20381202)
53. Velasco R, Bruna J, (2010). Chemotherapy-induced peripheral neuropathy: an unresolved issue. Neurologia 25: 116-131.
54. Velasco R, Petit J, Clapés V, Verdú E, Navarro X, Bruna J, (2010). Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst 15: 17-25.
55. Verdú E, Vilches JJ, Rodríguez FJ, Ceballos D, Valero A, Navarro X, (1999). Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice. Muscle Nerve 22: 329-340. (Pubitemid 29116186)
56. Watanabe T, Nagase K, Chosa M, Tobinai K, (2010). Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. Br J Cancer 103: 1580-1587.
57. Windebank AJ, Grisold W, (2008). Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13: 27-46. (Pubitemid 351393018)
58. Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, Battleman DS, (2008). Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol 6: 755-760.